D Schmidt, C Kollan, M Stoll - Frontiers in Public Health, 2024 - frontiersin.org
Background In Europe, the combination of cabotegravir (CAB) with rilpivirine (RPV) has
been approved as a dual injection long-acting (LA) therapy for the treatment of human …